InnoMedica’s Nanocarrier for Therapeutic Developments for Therapeutic Developmentsen
InnoMedica's Parkinson's therapy has the potential to bring about a paradigm shift – find out more in a market-based assessment by leading consulting firm IQVIA!
Find out now about the current offer for the capital increase – until September 30, 2025
Clear commitment to Switzerland as a centre
of production and research
Become part of our young and dynamic team
of experts from science and business
Innovation in the Service of Patients
InnoMedica is a Swiss pharmaceutical company dedicated to developing innovative medicines up to and including Phase II clinical development, based on its proprietary nano-transport technology platform. This technology is designed to deliver active pharmaceutical ingredients precisely to their site of action and enable controlled release at the target location. By doing so, it aims to enhance therapeutic efficacy while reducing systemic side effects — addressing one of the fundamental challenges in modern drug development: the efficient distribution of active substances within the human body.
In neurology, InnoMedica is developing a potentially novel therapy for Parkinson’s disease, targeting a significant unmet medical need. In parallel, a program in oncology demonstrates the broader applicability of the nanocarrier platform. Together, these initial programs highlight the versatility of the technology and its potential for additional indications as well as future partnerships in late-stage clinical development.
The well-equipped nanofactory, which has been expanded to include a second clean room, now guarantees coverage of the entire value chain from raw material and consumable material control through production to the stable, sterile, injectable end product in accordance with Good Manufacturing Practice (GMP) guidelines.
A liposomal formulation opens up new possibilities. InnoMedica's technology platform can be used for clinically established active pharmaceutical ingredients as well as for new, tailored substances such as RNA or proteins. There are barely any limits to InnoMedica's product pipeline.
InnoMedica's team embodies creative thinking and innovation combined with professional expertise and patient proximity. Are you motivated to become part of the young and dynamic team and committed to InnoMedica's goal of giving patients access to a new generation of nanomedicines?
Our scientific publications document the progress of our research and demonstrate the quality, reproducibility, and clinical relevance of our development within the international scientific community.
